Scott North

19.3k total citations · 2 hit papers
193 papers, 7.6k citations indexed

About

Scott North is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Scott North has authored 193 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 125 papers in Pulmonary and Respiratory Medicine, 74 papers in Oncology and 50 papers in Cancer Research. Recurrent topics in Scott North's work include Prostate Cancer Treatment and Research (63 papers), Renal cell carcinoma treatment (56 papers) and Bladder and Urothelial Cancer Treatments (32 papers). Scott North is often cited by papers focused on Prostate Cancer Treatment and Research (63 papers), Renal cell carcinoma treatment (56 papers) and Bladder and Urothelial Cancer Treatments (32 papers). Scott North collaborates with scholars based in Canada, United States and Australia. Scott North's co-authors include Kim N., Christian Kollmannsberger, Toni K. Choueiri, Peter Venner, Brian I. Rini, Jennifer J. Knox, Fred Saad, Daniel Y.C. Heng, Bernhard J. Eigl and Wanling Xie and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Scott North

185 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

2009 1.5k citations Daniel Y.C. Heng, Mark Warren et al. Journal of Clinical Oncology profile →
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

2012 1.0k citations Kim N., Scott North et al. profile →

Peers

Countries citing papers authored by Scott North

Since Specialization

Citations

This map shows the geographic impact of Scott North's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott North with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott North more than expected).

Fields of papers citing papers by Scott North

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott North. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott North. The network helps show where Scott North may publish in the future.

Co-authorship network of co-authors of Scott North

This figure shows the co-authorship network connecting the top 25 collaborators of Scott North. A scholar is included among the top collaborators of Scott North based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott North. Scott North is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multicenter examination of contemporary penile prosthesis surgery infection prophylaxis practices 2025 ·The Journal of Sexual Medicine ·(unknown), (unknown), (unknown), (unknown), (unknown), Scott North, James M. Hotaling, Jay Simhan, Martin Gross, Faysal A. Yafi	0
2	CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). 2024 ·Journal of Clinical Oncology ·Neeraj Agarwal, Arun Azad, Joan Carles, Nobuaki Matsubara, Stéphane Oudard, Fred Saad, Axel S. Merseburger, Andrey Soares, Bradley A. McGregor, Bogdan Żurawski, Scott North, Marinos Tsiatas, Igor Bondarenko, (unknown), (unknown), Keerti Vardhan Sharma, (unknown), Roberta Ferraldeschi, Fong Wang, Sumanta K. Pal	20
3	Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304). 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), Ian D. Davis, Robert Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen Sandhu, M. Neil Reaume, David Pook, Francis Parnis, Scott North, Gavin Marx, John McCaffrey, Ray McDermott, Lisa G. Horvath, Mark Frydenberg, Simon Chowdhury, Kim N., Martin R. Stockler, Christopher Sweeney, (unknown)	3
4	Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer 2024 ·Current Oncology ·(unknown), Naveen S. Basappa, Scott North, Sunita Ghosh, Michael Kolinsky	1
5	1799P Real-world (RW) treatment (tx) patterns of metastatic prostate cancer (mPCa) with enhanced access to homologous recombination repair (HRR) genomic testing and poly ADP ribose polymerase inhibitor (PARPi) 2023 ·Annals of Oncology ·Steven Yip, (unknown), Michael Kolinsky, Kosuke Takemura, Thomas F. Tucker, Marc Freeman, (unknown), Pinaki Bose, (unknown), Tarek A. Bismar, D.Y.C. Heng, Joseph D. Ruether, Scott North, Nimira Alimohamed, Naveen S. Basappa, Safiya Karim, (unknown), Adam Kinnaird, K.N. Chi, Soufiane El Hallani	1
6	1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304) 2023 ·Annals of Oncology ·Lisa G. Horvath, Ian D. Davis, Andrew Martin, (unknown), Alastair Thomson, Thean Hsiang Tan, Shahneen Sandhu, M. Neil Reaume, David Pook, Francis Parnis, Scott North, Gavin Marx, John A. McCaffrey, Ray McDermott, Nicola Jane Lawrence, Mark Frydenberg, S. Chowdhury, K.N. Chi, Martin R. Stockler, Christopher J. Sweeney	2
7	Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy 2022 ·European Journal of Cancer ·Jeffrey Graham, J. Connor Wells, Shaan Dudani, Chun Loo Gan, Frede Donskov, Jae‐Lyun Lee, Christian Kollmannsberger, Luís Meza, Benoit Beuselinck, Aaron R. Hansen, Scott North, Georg A. Bjarnason, Nicolas Sayegh, Ravindran Kanesvaran, Lori Wood, Sébastien J. Hotte, Rana R. McKay, Toni K. Choueiri, Daniel Y.C. Heng	20
8	Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada 2020 ·Bladder Cancer ·Di Jiang, Scott North, Christina Canil, Michael Kolinsky, Lori Wood, Samantha Gray, Bernhard J. Eigl, Naveen S. Basappa, Normand Blais, Eric Winquist, Som D. Mukherjee, Christopher M. Booth, Nimira Alimohamed, Piotr Czaykowski, Girish S. Kulkarni, Peter C. Black, Peter Chung, Wassim Kassouf, Theodorus van der Kwast, Srikala S. Sridhar	2
9	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium 2019 ·European Urology Oncology ·Jeffrey Graham, J. Connor Wells, Frede Donskov, Jae‐Lyun Lee, Anna Paola Fraccon, Felice Pasini, Camillo Porta, I. Alex Bowman, Georg A. Bjarnason, D. Scott Ernst, Sun Young Rha, Benoit Beuselinck, Aaron R. Hansen, Scott North, Christian Kollmannsberger, Lori Wood, Ulka N. Vaishampayan, Sumanta K. Pal, Toni K. Choueiri, Daniel Y.C. Heng	31
10	Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma 2019 ·Canadian Urological Association Journal ·Mark Warren, Michael Kolinsky, Christina M. Canil, Piotr Czaykowski, Srikala S. Sridhar, Peter C. Black, Christopher M. Booth, Wassim Kassouf, Libni Eapen, Som D. Mukherjee, Normand Blais, Bernhard J. Eigl, Eric Winquist, Naveen S. Basappa, Scott North	9
11	2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC) 2019 ·Canadian Urological Association Journal ·Fred Saad, Armen Aprikian, Antonio Finelli, Neil Fleshner, Martin Gleave, Anil Kapoor, Tamim Niazi, Scott North, Frédéric Pouliot, Ricardo Rendon, Bobby Shayegan, Srikala S. Sridhar, Alan So, Nawaid Usmani, Éric Vigneault, Kim N.	26
12	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer 2017 ·Clinical Cancer Research ·Gillian Vandekerkhove, Tilman Todenhöfer, Matti Annala, Werner J. Struss, Amanda Wong, Kevin Beja, Elie Ritch, Sonal Brahmbhatt, Stanislav Volik, Jörg Hennenlotter, Matti Nykter, Kim N., Scott North, Arnulf Stenzl, Colin C. Collins, Bernhard J. Eigl, Peter C. Black, Alexander W. Wyatt	122
13	Real-world Outcomes in Advanced Urothelial Cancer and the Role of Neutrophil to Lymphocyte Ratio 2017 ·Clinical Genitourinary Cancer ·Steven Yip, (unknown), Haocheng Li, Scott North, Daniel Yick Chin Heng, Nimira Alimohamed	7
14	Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience 2016 ·Annals of Oncology ·Aly‐Khan A. Lalani, (unknown), D.Y.C. Heng, Lori Wood, (unknown), Georg A. Bjarnason, (unknown), Christian Kollmannsberger, Anil Kapoor, Sébastien J. Hotte, Marie Vanhuyse, Piotr Czaykowski, M. Neil Reaume, Denis Soulières, Peter Venner, Scott North, Naveen S. Basappa	3
15	Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer 2015 ·The Journal of Clinical Pharmacology ·Kim N., Jennifer L. Spratlin, Christian Kollmannsberger, Scott North, (unknown), Martha Gonzalez, (unknown), Hans Stieltjes, (unknown), James Jiao, Milin Acharya, Thian Kheoh, Thomas W. Griffin, Margaret K. Yu, Caly Chien, Nam Phuong Tran	82
16	A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma 2014 ·Clinical Genitourinary Cancer ·Nimira Alimohamed, (unknown), Sandy Srinivas, Georg A. Bjarnason, Jennifer J. Knox, Mary J. MacKenzie, Lori Wood, Ulka N. Vaishampayan, Min-Han Tan, Sun Young Rha, Frede Donskov, Srinivas K. Tantravahi, Christian Kollmannsberger, Scott North, Brian I. Rini, Toni K. Choueiri, Daniel Y.C. Heng	27
17	CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC): 2013 Update 2013 ·Canadian Urological Association Journal ·Fred Saad, Sébastien J. Hotte, Charles Catton, Darrel Drachenberg, Antonio Finelli, Neil Fleshner, Martin Gleave, Anil Kapoor, Wassim Kassouf, Andrew Loblaw, Scott North, Nawaid Usmani, Kim N.	15
18	Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials 2013 ·Annals of Oncology ·D.Y.C. Heng, Toni K. Choueiri, Brian I. Rini, (unknown), Takeshi Yuasa, Sumanta K. Pal, S. Srinivas, Georg A. Bjarnason, Jennifer J. Knox, Mary J. MacKenzie, Ulka N. Vaishampayan, Min Tan, Sun Young Rha, Frede Donskov, N. Agarwal, Christian Kollmannsberger, Scott North, Lori Wood	113
19	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients 2013 ·Targeted Oncology ·(unknown), Brian I. Rini, Lauren C. Harshman, Georg A. Bjarnason, Lori Wood, Ulka N. Vaishampayan, Mary J. MacKenzie, Jennifer J. Knox, Neeraj Agarwal, (unknown), Christian Kollmannsberger, Min-Han Tan, Sun Young Rha, Frede Donskov, Scott North, Toni K. Choueiri, Daniel Y.C. Heng	39
20	A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC) 2007 ·Journal of Clinical Oncology ·(unknown), Sébastien J. Hotte, Evan Y. Yu, Bernhard J. Eigl, I. Tannock, Fred Saad, Scott North, Joseph D. Powers, E. Eisenhauer	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact